Home Editorial Repurposing of Drugs for Non-responding Erythema Nodosum Leprosum Cases – A Perspective

Repurposing of Drugs for Non-responding Erythema Nodosum Leprosum Cases – A Perspective

by admin
Published on:August 2022
Journal of Young Pharmacists, 2022; 14(3):266-267
Editorial | doi:10.5530/jyp.2022.14.53
Authors:
Pugazhenthan Thangaraju1,*, Sree Sudha TY2, Sajitha Venkatesan3
1Department of Pharmacology, AIIMS, Raipur, Chhattisgarh, INDIA.
2Department of Pharmacology, AIIMS, Deogarh, Jharkhand, INDIA.
3Department of Microbiology, AIIMS, Raipur, Chhattisgarh, INDIA.
Abstract:

Leprosy (Hansen’s disease) caused by Mycobacterium lepra is a debilitating tropical disease having maximal stigma till date. Efforts have been made for many decades to keep disease incidence under control. In 2019, 202,185 new cases of leprosy were reported around the world, with 14,981 (7.4%) of those found in children under the age of 15.1-3 Globally in 2020, 1, 28,405 new leprosy patients were diagnosed. New paediatric cases were 8661 diagnosed with leprosy and 7216 patients with grade 2 disability by WHO region. Read more. . .